Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy

doi:10.4254/wjh.v16.i3.405

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1681)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

138

HTML

699

Figures (1-4)

211

Tables (1-2)

158

Sum=1206

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

330

Sum=397

Mar 27, 2024 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Mar 27, 2024; 16(3): 405-417
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.405

Full Size Figure Download Figure

Figure 1 Kinetics of serum markers in patients with chronic hepatitis B during peginterferon alpha treatment and follow-up between responders and non-responders. A: Alanine aminotransferase; B: Hepatitis B virus DNA; C: Hepatitis B surface antigen; D: Hepatitis B e antigen. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. RS: Responders; NRS: Non-responders; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.

Citation: Zhang PX, Zheng XW, Zhang YF, Ye J, Li W, Tang QQ, Zhu J, Zou GZ, Zhang ZH. Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy. World J Hepatol 2024; 16(3): 405-417
URL: https://www.wjgnet.com/1948-5182/full/v16/i3/405.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i3.405